Skip to Main Content

Latest News

April 21, 2008
Volume 86, Number 16
p. 9

Pharmaceuticals

AstraZeneca And Ranbaxy Settle Suit

Nexium agreement still has to get past regulators

Lisa Jarvis

AstraZeneca and Ranbaxy Laboratories have settled a patent lawsuit over Nexium, AstraZeneca's blockbuster heartburn drug.

AstraZeneca

Under the agreement, Ranbaxy can start selling a generic version of Nexium in May 2014. In the meantime, the Indian firm will become AstraZeneca's U.S. distributor for generic versions of two of its older drugs. Ranbaxy will also manufacture esomeprazole, the active pharmaceutical ingredient (API) in Nexium, for AstraZeneca starting in 2009. AstraZeneca says the arrangement furthers its previously announced strategy to exit API manufacturing over the next five to 10 years.

The pact has yet to pass muster with regulatory authorities. The Federal Trade Commission (FTC) appears to be growing weary of "authorized generics" deals in which drug companies essentially pay to keep competition off the market.

In 2005, Ranbaxy cut a similar deal with the biotech firm Cephalon. Ranbaxy agreed to drop its patent challenge on Cephalon's flagship drug, Provigil, in exchange for a nonexclusive license to market a generic version of the narcolepsy drug starting in October 2011. That deal also included a manufacturing arrangement under which Ranbaxy was hired to supply the API for Provigil.

Earlier this year, FTC sued Cephalon for "a course of anticompetitive conduct" related to its Provigil agreements with Ranbaxy and three other generic drug firms. The agency charges that Cephalon paid the generics companies more than $200 million to delay competition between generics and the patented drug.

AstraZeneca's deal with Ranbaxy does not include a direct payment. "There is no payment being made for this, and there have been a number of settlements like this done in the past," AstraZeneca CEO David Brennan told reporters during a conference call.

Still, observers say the manufacturing contract and other agreements could be viewed as simply another form of financial incentive for Ranbaxy to back off. YeeWah Chin, an antitrust lawyer with New York City's Ingram Yuzek Gainen Carroll & Bertolotti, says such incentives set red flags waving at FTC.

"The question becomes whether it's a sham," Chin says. FTC, she adds, will weigh whether the manufacturing and distribution deals are priced appropriately and whether AstraZeneca's patents would have held up in court.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society

Related Stories

Adjust text size:

A- A+

Articles By Topic